公开(公告)号：US20130259858A1

公开(公告)日：2013-10-03

申请号：US13829234

申请日：2013-03-14

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Eldad Zacksenhaus ,  Jeff Liu

IPC: C12Q1/68 ,  G01N33/74

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/74

Abstract: A method of predicting outcome in a subject with for example Her2+ (ERα−) breast cancer comprising: a. determining a HTICs expression signature comprising determining an expression level of 2 or more HTICS biomarkers selected from Aurkb, Ccna2, Scrn1, Npy, Atp7b, Chaf1b, Ccnb1 Cldn8, Nrp1, Ccr2, C1qb, Cd74, Vcam1, Cd180, Itgb2, Cd72, St8sia4 Kif11, Plk1, Chek1, Mphosph6, Coro1a, Ccl5, Cd3e Hcls1, Vav1, Plek, Arhgdib, Il2rg, Sash3, Lck, Il2rb, Cybb, Cd79b, Sell, Ccnd2, Tnfrsf1b, Rftn1, Rac2 and Ly86; and b. calculating a signature score, the signature score comprising a sum of HTICs biomarker expression parameters; wherein a signature score greater than a selected cut-off or control signature score is indicative of a poor outcome (HTICS+) and a signature score less than a selected cut-off is indicative of a good outcome (HTICS−). The methods can be used to prognose outcome and/or select suitable treatment. Arrays and kits for use with the methods are also provided.

Abstract translation: 一种用例如Her2 +（ERα-））乳腺癌预测受试者的结局的方法，包括：a。 确定HTICs表达特征，其包括确定选自Aurkb，Ccna2，Scrn1，Npy，Atp7b，Chaf1b，Ccnb1 Cldn8，Nrp1，Ccr2，C1qb，Cd74，Vcam1，Cd180，Itgb2，Cd72，St8sia4中的2种或更多种HTICS生物标志物的表达水平 Kif11，Plk1，Chek1，Mhosph6，Coro1a，Ccl5，Cd3e Hcls1，Vav1，Plek，Arhgdib，Il2rg，Sash3，Lck，Il2rb，Cybb，Cd79b，Sell，Ccnd2，Tnfrsf1b，Rftn1，Rac2和Ly86; 和b。 计算签名分数，所述签名评分包括HTICs生物标记表达参数之和; 其中大于所选择的截止或控制签名得分的签名得分表示不良结果（HTICS +），而小于选择的截止值的签名评分表示良好结果（HTICS-）。 该方法可用于预测结果和/或选择合适的治疗。 还提供了与方法一起使用的数组和试剂盒。

公开(公告)号：US09803245B2

公开(公告)日：2017-10-31

申请号：US13829234

申请日：2013-03-14

Applicant: University Health Network

Inventor： Eldad Zacksenhaus ,  Jeff Liu

IPC: C12Q1/68 ,  G01N33/74 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/74

Abstract: A method of predicting outcome in a subject with for example Her2+ (ERα−) breast cancer comprising: (a) determining a HTICs expression signature comprising determining an expression level of 2 or more HTICS biomarkers selected from Aurkb, Ccna2, Scrn1, Npy, Atp7b, Chaf1b, Ccnb1, Cldn8, Nrp1, Ccr2, C1qb, Cd74, Vcam1, Cd180, Itgb2, Cd72, St8sia4, Kif11, Plk1, Chek1, Mphosph6, Cora1a, Ccl5, Cd3e, Hcls1, Vav1, Plek, Arhgdib, Il2rg, Sash3, Lck, Il2rb, Cybb, Cd79b, Sell, Ccnd2, Tnfrsf1b, Rftn1, Rac2 and Ly86; and (b) calculating a signature score, the signature score comprising a sum of HTICs biomarker expression parameters; wherein a signature score greater than a selected cut-off or control signature score is indicative of a poor outcome (HTICS+) and a signature score less than a selected cut-off is indicative of a good outcome (HTICS−). The methods can be used to prognose outcome and/or select suitable treatment. Arrays and kits for use with the methods are also provided.